BRAF (B-raf proto-oncogene)

P2, N=20, Active, not recruiting, Melanoma Institute Australia | Trial completion date: Jan 2036 --> Oct 2035

P=N/A, N=2, Completed, University of California, Los Angeles | Recruiting --> Completed | N=125 --> 2

P1, N=57, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting

P1, N=16, Terminated, Rutgers, The State University of New Jersey | Active, not recruiting --> Terminated; accrual goal met

P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

Multiplex immunofluorescence staining demonstrated that BCL-xL inhibition effectively triggered apoptosis in heterogeneous PDX tumor slice models, including models harboring oncogenic BRAF mutations. Our findings suggest that cetuximab-resistant CRC retains apoptotic competence, and that BCL-xL inhibition serves as a robust alternative therapeutic strategy that is largely independent of the tumor mutational profile.

P3, N=480, Recruiting, University of Campania Luigi Vanvitelli

P1/2, N=24, Not yet recruiting, University of Chicago

Eighty-three percent of CR-NEC received first-line platinum-etoposide, while 98% of CR-AC patients received first-line fluorouracil-based chemotherapy. Metastatic CR-NEC and CR-AC are clinically distinct, with NEC demonstrating more aggressive features, limited treatment effect, and worse prognosis. Although they share important driver mutations, the underlying reason for their marked clinical differences remains unclear.

P3, N=254, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Jun 2031 | Trial primary completion date: Sep 2027 --> Jun 2028

P2, N=93, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Phase classification: P1/2 --> P2

P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | N=20 --> 30